Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Chief Operating Officer
On January 26, 2021, the Board of Directors of Adaptive Biotechnologies
Corporation (the "Company") appointed Mark Adams as Chief Operating Officer of
the Company, effective January 25, 2021. Dr. Adams, 53, joined the Company in
April 2020 as Chief Technical Officer. Additional biographical information
regarding Dr. Adams is set forth in the Company's definitive proxy statement
filed on April 24, 2020, which is incorporated by reference herein.
Dr. Adams' annual salary will be increased to $430,000, and his fiscal year
annual incentive opportunity will be equal to 50% of his base salary. As Chief
Operating Officer, Dr. Adams is entitled to the severance benefits of an
Executive Vice President under the Company's form of Executive Severance
Agreement, and he may also participate in other standard Company benefit
programs.
Departure of Executive Vice President, Operations and Program Management
On January 21, 2021, the Company and Nancy Hill agreed that her tenure as
Company's Executive Vice President, Operations and Program Management will be
terminated, effective March 2, 2021. Ms. Hill's termination is not the result of
any material disagreement with the Company regarding its operations, policies,
or practices.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses